
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Reagan-Udall Foundation, the non-profit foundation for the FDA, launched a new website called Expanded Access Navigator. It features a pharma company directory of expanded access policies and criteria, along with educational resources, guides, and downloadable forms.
The American Cancer Society, the American Society of Clinical Oncology, the Biotechnology Industry Association, FDA, Foundation Medicine, PhRMA and Susan G. Komen helped develop the Navigator along with the support of Bristol-Meyers Squibb, Genentech, Janssen, Lilly, Merck and Pfizer.






